Allogene Therapeutics Announces Participation in March Investor Conference
Allogene Therapeutics (Nasdaq: ALLO), a clinical-stage biotech company focused on developing allogeneic CAR T (AlloCAR T™) therapies for cancer and autoimmune diseases, has announced its upcoming participation in the TD Cowen 45th Annual Health Care Conference. The presentation is scheduled for March 5, 2025, at 8:20 AM PT/11:50 AM ET.
The company will make webcasts available on their website www.allogene.com under the Investors tab, with replays accessible for approximately 30 days after the event.
Allogene Therapeutics (Nasdaq: ALLO), un'azienda biotech in fase clinica focalizzata sullo sviluppo di terapie CAR T allogeniche (AlloCAR T™) per il cancro e le malattie autoimmuni, ha annunciato la sua prossima partecipazione alla 45ª Conferenza Annuale sulla Salute di TD Cowen. La presentazione è programmata per il 5 marzo 2025, alle 8:20 AM PT/11:50 AM ET.
L'azienda renderà disponibili webcast sul proprio sito www.allogene.com sotto la sezione Investitori, con registrazioni accessibili per circa 30 giorni dopo l'evento.
Allogene Therapeutics (Nasdaq: ALLO), una empresa biotecnológica en etapa clínica centrada en el desarrollo de terapias CAR T alogénicas (AlloCAR T™) para el cáncer y enfermedades autoinmunes, ha anunciado su próxima participación en la 45ª Conferencia Anual de Salud de TD Cowen. La presentación está programada para el 5 de marzo de 2025, a las 8:20 AM PT/11:50 AM ET.
La empresa hará disponibles webcasts en su sitio web www.allogene.com en la pestaña de Inversores, con repeticiones accesibles durante aproximadamente 30 días después del evento.
Allogene Therapeutics (Nasdaq: ALLO)는 암 및 자가면역 질환을 위한 동종 CAR T(AlloCAR T™) 치료제를 개발하는 임상 단계의 생명공학 회사로, TD Cowen 제45회 연례 건강 관리 컨퍼런스에 참여할 예정이라고 발표했습니다. 발표는 2025년 3월 5일 오전 8:20 PT/오후 11:50 ET에 예정되어 있습니다.
회사는 웹사이트 www.allogene.com의 투자자 탭에서 웹캐스트를 제공하며, 이벤트 이후 약 30일 동안 다시 볼 수 있습니다.
Allogene Therapeutics (Nasdaq: ALLO), une entreprise de biotechnologie en phase clinique axée sur le développement de thérapies CAR T allogéniques (AlloCAR T™) pour le cancer et les maladies auto-immunes, a annoncé sa prochaine participation à la 45e Conférence Annuelle sur la Santé de TD Cowen. La présentation est prévue pour le 5 mars 2025 à 8h20 PT/11h50 ET.
L'entreprise mettra à disposition des webcasts sur son site www.allogene.com sous l'onglet Investisseurs, avec des rediffusions accessibles pendant environ 30 jours après l'événement.
Allogene Therapeutics (Nasdaq: ALLO), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von allogenen CAR T (AlloCAR T™) Therapien für Krebs und Autoimmunerkrankungen konzentriert, hat seine bevorstehende Teilnahme an der 45. jährlichen Gesundheitskonferenz von TD Cowen angekündigt. Die Präsentation ist für den 5. März 2025 um 8:20 Uhr PT/11:50 Uhr ET geplant.
Das Unternehmen wird Webcasts auf seiner Website www.allogene.com unter dem Reiter Investoren zur Verfügung stellen, mit Wiederholungen, die etwa 30 Tage nach der Veranstaltung zugänglich sind.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will participate in one upcoming investor conference in March.
TD Cowen 45th Annual Health Care Conference
Wednesday, March 5, 2025
8:20AM PT/11:50AM ET
Any available webcasts will be posted to the Company's website at www.allogene.com under the Investors tab in the News and Events section. Following a live webcast, a replay will be available on the Company's website for approximately 30 days.
About Allogene Therapeutics
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) products for cancer and autoimmune disease. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of “off-the-shelf” CAR T cell product candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients. For more information, please visit www.allogene.com, and follow Allogene Therapeutics on X and LinkedIn.
Cautionary Note on Forward-Looking Statements for Allogene
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things Allogene’s ability to develop and deliver readily available allogeneic CAR T products for the treatment of cancer and autoimmune disease on-demand, more reliably, and at greater scale to more patients. Various factors may cause material differences between Allogene’s expectations and actual results, including risks and uncertainties related to our product candidates being based on novel technologies, which makes it difficult to predict the time and cost of product candidate development, the safety or efficacy of a product candidate, and whether a product candidate will receive regulatory approval, which could prevent or delay commercialization. These and other risks are discussed in greater detail in Allogene’s filings with the SEC, including without limitation under the “Risk Factor” heading in its Quarterly Report on Form 10-Q for the quarter ended September 30, 2024. Any forward-looking statements that are made in this press release speak only as of the date of this press release. Allogene assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
AlloCAR T™ is a trademark of Allogene Therapeutics, Inc.
Allogene Media/Investor Contact:
Christine Cassiano
EVP, Chief Corporate Affairs & Brand Strategy Officer
Christine.Cassiano@allogene.com
FAQ
When is Allogene Therapeutics (ALLO) presenting at the TD Cowen Healthcare Conference 2025?
Where can investors watch Allogene Therapeutics' (ALLO) TD Cowen conference presentation?
How long will Allogene Therapeutics' (ALLO) conference webcast be available for replay?
What therapeutic areas is Allogene Therapeutics (ALLO) focusing on with their AlloCAR T products?
